The U.S. Food and Drug Administration (FDA) today announced that it is initiating action to remove concentrated ingestible fluoride prescription drug products for children from the market. Unlike toothpaste with fluoride or fluoride rinses, these products are swallowed and ingested by infants and toddlers. They have also never been approved by the FDA. Ingested fluoride has been shown to alter the gut microbiome, which is of magnified concern given the early development of the gut microbiome in

日前，国家医保局发布了《关于开展智能监管改革试点的通知》，这一举措标志着我国医疗保障体系在智能化、数字化转型道路上迈出了重要一步。近年来，随着我国经济快速发展和社会老龄化加剧，医保基金的压力日益增大，如何高效管理并合理使用医保基金成为亟待解决的问题。据国家医保局数据显示，2024年全国共追回医保基金超270亿元，监管压力持续加大。传统人工审核模式效率低、覆盖面窄，难以应对海量医疗数据筛查需求。 在此背景下，智能监管改革试点应运而生。其核心目标在于通过引入大数据分析、人工智能、区块链等前沿技术手段，构建一个更加透明、公正且高效的医保基金监管体系。具体来说，智能监管改革旨在实现对医保数据的实时监测与动态分析，及时发现异常行为，并采取有效措施进行干预，从源头上遏制欺诈骗保行为，推动医疗行为合规化，从而提高医保资金使用的安全性和合理性。同时，借助智能技术，还可以优化医保报销流程，减少人为干预，提升服务质量和患者满意度。 此次试点工作的启动，不仅是对现有医保监管模式的一次重大革新，更是为了适应新时代下医疗保障需求的变化。那此次试点通知的发布，都释放了哪些信号呢？今天和大家做个简单的分享，仅供参考

MAY 6, 2025 – Today, CityHealth, an initiative of the de Beaumont Foundation and Kaiser Permanente, awarded the City of Omaha its first overall bronze medal — recognizing the city’s leadership for advancing six high-quality policies that support the health and well-being of its residents. The announcement was made at today’s city council meeting, where councilmembers accepted the overall bronze medal and celebrated this significant milestone. In 2024, Omaha was the only city in the nation to ear

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) disorder. Regulatory approval for the Phase II trial in PNH subjects was granted based on the safety profile of healthy subjects in the Phase I trial. Interim results from this 12-subject, three-month, multi-dose Phase II efficacy trial are compelling. The drug was safe and well-to

May 19, 2025 -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dated April 1, 2024 between the Company, Aditxt, and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”) (as amended on July 1, 2024 and f

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase 1 APOLLO study expected later this year May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of h

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adverse events related to PM359 -- -- Initiating efforts to explore continued clinical development oppo

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform, an AI and stem cell secretome-based drug discovery and development platform May 19, 2025 -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced today that it is enrolling participants in

May 15, 2025 -- Pathos AI, a leading AI-driven biotech company applying cutting-edge artificial intelligence to drug development, today announced its $365 million Series D financing, bringing its post-money valuation to approximately $1.6 billion. This financing marks a major milestone for Pathos as it expands its AI-enabled platform to drive greater speed, precision, and success in oncology drug development. The proceeds will support advancement of the company’s clinical-stage pipeline and c

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzh